Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature

被引:3
|
作者
Sampieri, C. L. [1 ]
Orozco-Ortega, R. A. [2 ]
机构
[1] Univ Veracruzana, Inst Salud Publ, Av Luis Castelazo Ayala S-N, Xalapa 91190, Veracruz, Mexico
[2] Univ Veracruzana, Fac Bioanal, Xalapa, Veracruz, Mexico
关键词
Matrix metalloproteinases; tissue inhibitors of metalloproteinases; chronic kidney disease; acute kidney injury; URINARY BIOMARKERS; MATRIX-METALLOPROTEINASE-9; SERUM; STORAGE; DYSREGULATION; DEGRADATION; ZYMOGRAPHY; MORTALITY; MARKER; BLOOD;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers. Material and methods: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine. Results: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families. Discussion: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [41] Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
    Zdenka Navratilova
    Vitezslav Kolek
    Martin Petrek
    Archivum Immunologiae et Therapiae Experimentalis, 2016, 64 : 177 - 193
  • [42] Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
    Navratilova, Zdenka
    Kolek, Vitezslav
    Petrek, Martin
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2016, 64 (03) : 177 - 193
  • [43] MATRIX METALLOPROTEINASES AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES EXPRESSION BY TUBULAR EPITHELIA AND INTERSTITIAL FIBROBLASTS IN THE NORMAL KIDNEY AND IN FIBROSIS
    NORMAN, JT
    GATTI, L
    WILSON, PD
    LEWIS, M
    EXPERIMENTAL NEPHROLOGY, 1995, 3 (02): : 88 - 89
  • [44] Matrix metalloproteinases in kidney homeostasis and diseases
    Tan, Roderick J.
    Liu, Youhua
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2012, 302 (11) : F1351 - F1361
  • [45] Kidney Fibrosis and Matrix Metalloproteinases (MMPs)
    La Russa, Antonella
    Serra, Raffaele
    Faga, Teresa
    Crugliano, Giuseppina
    Bonelli, Angelica
    Coppolino, Giuseppe
    Bolignano, Davide
    Battaglia, Yuri
    Ielapi, Nicola
    Costa, Davide
    Michael, Ashour
    Andreucci, Michele
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (05):
  • [46] EXPRESSION OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN PANCREATIC-CARCINOMA AND CHRONIC-PANCREATITIS
    GRESS, TM
    MULLERPILLASCH, F
    LERCH, MM
    BEGER, H
    FRIESS, H
    BUCHLER, M
    ADLER, G
    GASTROENTEROLOGY, 1995, 108 (04) : A476 - A476
  • [47] Tissue inhibitors of matrix metalloproteinases in cancer
    Blavier, L
    Henriet, P
    Imren, S
    DeClerck, YA
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 108 - 119
  • [48] Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling
    Li, YY
    McTiernan, CF
    Feldman, AM
    CARDIOVASCULAR RESEARCH, 2000, 46 (02) : 214 - 224
  • [49] Expression of Tissue Levels of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Gastric Adenocarcinoma
    Zhang, Ming
    Zhu, Guan-Yu
    Gao, Hong-Yu
    Zhao, Shu-Peng
    Xue, Yingwei
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (03) : 243 - 247
  • [50] Matrix metalloproteinases and their tissue inhibitors in endocrinology
    Salamonsen, LA
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1996, 7 (01): : 28 - 34